The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms
Summary Background & Aims Prevalence of hepatitis C virus (HCV) infection in the Netherlands is low (anti-HCV prevalence 0.22%). All-oral treatment with direct-acting antivirals (DAAs) is tolerable and effective but expensive. Our analysis projected the future HCV-related disease burden in the Netherlands by applying different treatment scenarios. Methods Using a modelling approach, the size of […]
English 
Spanish 
French 
Russian 
Arabic